Increasing the Effectiveness of Oncolytic Adenoviruses for Colon Cancer
Author Information
Author(s): Christophe Fuerer, Krisztian Homicsko, Alexander N Lukashev, Anne-Laure Pittet, Richard D Iggo
Primary Institution: NCCR Molecular Oncology Programme, Swiss Institute for Experimental Cancer Research (ISREC), Epalinges, Switzerland
Hypothesis
Fusing the BCL9 HD2 domain to E1A will enhance the cytopathic effect of oncolytic adenoviruses targeting colon cancer cells.
Conclusion
Fusing E1A to the BCL9 HD2 domain increased the nuclear pool of β-catenin but resulted in only small changes in viral activity in colon cancer cells.
Supporting Evidence
- The E1A-HD2 fusion protein binds to β-catenin and enhances its nuclear localization.
- Viruses expressing the E1A-HD2 fusion showed a five-fold increase in cytopathic effect in colorectal cancer cell lines.
- Despite increased in vitro activity, the E1A-HD2 virus did not show improved anti-tumor efficacy in vivo.
Takeaway
The study tried to make a virus better at killing colon cancer cells by adding a special part to it, but it didn't work as well as hoped in real tumors.
Methodology
The study used luciferase assays, co-immunoprecipitation, Western blotting, immunofluorescent staining, and cytopathic effect assays to evaluate the effects of the E1A-HD2 fusion protein.
Limitations
The increase in cytopathic effect observed in vitro did not translate to improved efficacy in vivo, indicating potential limitations in the model used.
Participant Demographics
The study involved female NMRI nu/nu mice for xenograft experiments.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website